Firibastat (also known as RB150, and QGC-001) is used in the treatment of hypertension. Firibastat is an aminobutane-1-sulfonic acid derivative patented as an antihypertensive agent. Firibastat acts as aminopeptidase A (APA) inhibitor and suppresses the conversion of angiotensin II to angiotensin III in brain tissues. RB150 was renamed firibastat by the World Health Organization (WHO). Phase Ia/Ib clinical trials showed that firibastat is clinically and biologically well tolerated in healthy volunteers. Clinical efficacy of firibastat in hypertensive patients was demonstrated in 2 phase II studies. Firibastat represents the first drug of a novel class of antihypertensive drugs targeting the brain renin-angiotensin system.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Firibastat (QGC-001), just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.